Shares of Soleno Therapeutics (SLNO) are up 35% or $17.03 at $66.00 after the stock resumed trading. Shares had been halted ahead of the company announcement of FDA approval of VYKAT XR to treat hyperphagia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO: